Simulect

DRUG6 trials

Sponsors

Astellas Pharma Inc, Novartis Pharmaceuticals, University Hospital, Toulouse, Centre Hospitalier Universitaire de Saint Etienne

Conditions

GlomerulonephritisIgANKidney TransplantationRenal Transplant RejectionRenal Transplantation

Phase 3

Comparison of Standard Versus Low Dose Advagraf® With or Without Angiotensin-converting Enzyme Inhibitor (ACEi)/Angiotensin Receptor Blocker (ARB) on Histology and Function of Renal Allografts

CompletedNCT00933231

Astellas Pharma IncKidney Transplantation

Start: 2009-08-17End: 2018-04-03Updated: 2024-11-01

12 Month Athena Study: Everolimus vs. Standard Regimen in de Novo Kidney Transplant Patients

CompletedNCT01843348

Novartis PharmaceuticalsKidney Transplantation, Renal Transplantation

Start: 2012-12-27End: 2016-03-23Updated: 2017-05-01

Phase 4

A Study in Kidney Transplant Subjects to Investigate the Optimal Suppression of Immunity to Help Prevent Kidney Rejection

CompletedNCT00717470

Astellas Pharma IncKidney Transplantation

Start: 2008-05-14End: 2010-03-02Updated: 2024-11-01

A Study Looking at Diabetes in Kidney Transplant Recipients Receiving Immunosuppressive Regimen With or Without Steroids

CompletedNCT01304836

Astellas Pharma IncKidney Transplantation

Start: 2011-01-22End: 2013-05-22Updated: 2024-11-01

Simulect Versus ATG in Sensitized Renal Transplant Patient

CompletedNCT02377193

University Hospital, ToulouseRenal Transplant Rejection

Start: 2013-09-30End: 2017-01-31Updated: 2025-12-10

Prevention in Recipients With Primary IgA Nephropathy of Recurrence After Kidney Transplantation: ATG-F Versus Basiliximab as Induction Immunosuppressive Treatment

TerminatedNCT02523768

Centre Hospitalier Universitaire de Saint EtienneGlomerulonephritis, IgAN

Start: 2011-01-08End: 2020-02-24Updated: 2021-01-20

Related Papers

A Five‐Year Prospective, Randomized, Open‐Label Study of Standard‐Dose Versus Low‐Dose Prolonged‐Release Tacrolimus With or Without Angiotensin‐Converting Enzyme Inhibitor or Angiotensin II Receptor Blocker Post Kidney Transplantation

Clinical Transplantation2024-12-30

Impact of everolimus plus calcineurin inhibitor on formation of non-HLA antibodies and graft outcomes in kidney transplant recipients: 12-month results from the ATHENA substudy

Frontiers in Transplantation2023-11-214 citations

COUNTRY-DEPENDENT OUTCOME DIFFERENCES AFTER KIDNEY TRANSPLANTATION IN FRANCE VS. GERMANY – AN ADDITIONAL ANALYSIS OF THE ATHENA STUDY

Transplantation2020-08-28

ATHENA VS HEPHAISTOS - ARE DISCONTINUATION RATES IN MULTICENTER STUDIES DRIVEN BY FACTS OR ATTITUDES?

Transplantation2020-08-28

Comparison of the effects of standard vs low-dose prolonged-release tacrolimus with or without ACEi/ARB on the histology and function of renal allografts.

2019-02-0126 citations

Efficacy of Prolonged- and Immediate-release Tacrolimus in Kidney Transplantation: A Pooled Analysis of Two Large, Randomized, Controlled Trials.

2017-11-019 citations

Incidence of Posttransplantation Diabetes Mellitus in De Novo Kidney Transplant Recipients Receiving Prolonged-Release Tacrolimus-Based Immunosuppression With 2 Different Corticosteroid Minimization Strategies: ADVANCE, A Randomized Controlled Trial.

2017-08-0137 citations

Design and rationale of the ATHENA study--A 12-month, multicentre, prospective study evaluating the outcomes of a de novo everolimus-based regimen in combination with reduced cyclosporine or tacrolimus versus a standard regimen in kidney transplant patients: study protocol for a randomised controlled trial.

2016-02-1711 citations